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Common variable immunodeﬁciency (CVID) is one
of the most frequently diagnosed primary immun-
odeﬁciencies (PIDs) characterised by antibody
deﬁciency, poor responses to vaccination and an
increased susceptibility to infections and compli-
cations due to immune dysregulation. The clinical
diagnosis of CVID is an umbrella covering an
immunologically and genetically heterogeneous
group of diseases. To date, 22 disease-causing
genes have been associated with monogenic forms
of CVID, encompassing 2–10% of reported cases.
However, these genetic subtypes are now con-
sidered to account for distinct disease entities
and have been removed from under the CVID
umbrella. Furthermore, accumulating data sug-
gest that the majority of CVID patients have a
complex or multifactorial disorder, in which mul-
tiple genetic, epigenetic and/or environmental
factors are involved. Genetic testing for mono-
genic causes should especially be performed in
CVID patients with early onset of disease, nonin-
fectious complications, a positive family history
and/or consanguineous parents, since this could
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be important for genetic counselling, follow up
and/or treatment decisions.
Introduction
Primary immunodeficiencies (PIDs) are diseases caused by
genetically determined defects in the immune system. Anno
2017, more than 300 genes have been associated with monogenic
forms of PID. The International Union of Immunological Soci-
eties (IUIS) has categorised PID disorders into eight groups based
on their most pronounced and fundamental defect. Predominantly
antibody deficiencies (PADs, also called primary antibody defi-
ciencies) form the largest group, accounting for 50–60% of all
registered PID patients (Picard et al., 2015). Common variable
immunodeficiency (CVID) is one of the most frequently diag-
nosed PADs, with an estimated prevalence between 1:100 000
and 1:10 000 worldwide. However, it is suspected that a consid-
erable number of CVID patients are left undiagnosed (Bonilla
et al., 2016). The term ‘CVID’ was introduced in 1971 by the
World Health Organization to distinguish less well-defined forms
of antibody deficiency from those with a more consistent phe-
notype and Mendelian inheritance. Hence, from the beginning,
CVID became a diagnosis of exclusion. During recent years, the
diagnostic criteria of CVID have been a topic of ongoing discus-
sion. The latest international consensus criteria from 2016 closely
resemble the original ones from 1999: amarked decrease in serum
immunoglobulin (Ig) G, decreased IgM and/or IgA, impaired
antibody responses to immunisation and exclusion of other
defined causes of hypogammaglobulinaemia. To rule out tran-
sient hypogammaglobulinaemia of infancy, a definite diagnosis
of CVID should not be given before 4 years of age (Bonilla et al.,
2016). CVID encompasses a heterogeneous patient population
eLS © 2017, John Wiley & Sons, Ltd. www.els.net 1
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Table 1 Overview of the most important immunological abnormalities described in CVID
B cells T cells Innate immune cells
↓Total B cells
↓B-cell bone marrow development
↓BCR signalling
↓BAFF-R expression (survival)
↑Fas expression (apoptosis)
↓Class-switched memory B cells
(IgM−IgD−CD27+)
↓Plasma cells in lymphoid organs
↓Somatic hypermutation
↓Marginal zone-like B cells
(IgM+IgD+CD27+)
↑Transitional B cells
(CD38highCD24highIgMhigh)
↑CD21low B cells (CD21lowCD38low)
↓CXCR5 and CCR7 expression
↓TLR7 and TLR9 signalling
↓Naive (or total) CD4+ T cells
↓Thymic output:
↓TRECs
↓CD4+ recent thymic emigrants
(CD45RA+CD31+)
↑Apoptosis
↓TCR repertoire
↓Treg cells
(CD4+CD25+FOXP3+/CD127−)
↓Treg-suppressive activity
↓Or↑circulating Tfh cells
(CD4+CD45RO+CXCR5+)
↑CD8+ T cells (mainly effector subsets)
↓T-cell proliferation responses to antigens
and TCR antibodies
Cytokine imbalance (e.g. ↓ IL-2)
Monocytes:
↑activity
↑IL-12 secretion
↓ phagocytosis
↓Conventional DCs
↓Plasmacytoid DCs
↓TLR7 and TLR9 signalling in pDCs
↓Maturation monocyte-derived DCs
↓NK cells
↓NKT cells
↓ Invariant NKT cells
↑IFN-𝛾+ IL-17A+ IL-22+ ILCs
↓, decreased; ↑, increased; BAFF-R, B-cell activating factor belonging to the TNF family receptor; BCR, B-cell receptor; CD, cluster of differentiation;
CVID, common variable immunodeficiency; DCs, dendritic cells; IFN, interferon; Ig, immunoglobulin; IL, interleukin; ILCs, innate lymphoid cells;
NK, natural killer; NKT, natural killer T; pDCs, plasmacytoid dendritic cells; TCR, T-cell receptor; Tfh, follicular helper T; TLR, Toll-like receptor;
TRECs, T-cell receptor excision circles; Treg, regulatory T.
demonstrating a diversity of clinical and immunological features
with varying severity. Disease onset can occur at any age from
infancy to late adulthood, with a peak incidence in childhood
and the third and fourth decades of life. Approximately 25% of
CVID patients receive a diagnosis before the age of 18. CVID
patients typically suffer from recurrent and/or severe infections,
mainly of the respiratory and gastrointestinal tracts. Repeated
infections of the lower airways may cause irreversible structural
damage such as bronchiectasis. Furthermore, patients are at
risk of complications due to immune dysregulation, including
autoimmunity, unexplained enteropathy, polyclonal lympho-
proliferation, granulomatous disease and/or malignancy. These
so-called noninfectious or disease-related complications can
develop any time during the disease course and can sometimes
be the first clinical presentation before the onset of infections.
Depending on the study cohort, between 33% and 80% of CVID
patients have an ‘infections-only’ phenotype, that is without
disease-related complications (Bonilla et al., 2016). The variable
clinical picture is accompanied by an equally variable immuno-
logical laboratory phenotype. The main immunological defect in
CVID is, by definition, impaired Ig production by plasma cells.
In addition, a plethora of immunological abnormalities in both
the adaptive and the innate immune system have been described
in CVID patients: numerical and/or functional alterations in B
cells, T cells, natural killer (NK) cells, NK T cells, monocytes,
dendritic cells and innate lymphoid cells (Table 1) (Bonilla et al.,
2016; Bogaert et al., 2017a). Importantly, each of the laboratory
features shown inTable 1 is only present in a subgroup of patients
and may also be normal or even deviant in the opposite direction
in other patients with CVID. The link between B cell, T cell
and innate immune cell abnormalities in disease development
is largely enigmatic. Immunological abnormalities across all
parts of the immune system appear to cluster together in patients
suffering from disease-related complications. Even in those
patients, however, the various immunological abnormalities are
unequally distributed across patient cohorts and no coherent
picture can be drawn. Furthermore, it is difficult to determine
whether immunological defects are primary (disease-intrinsic)
or secondary (e.g. caused by chronic inflammation), especially
because the underlying pathophysiological mechanisms are
largely unknown and likely to be heterogeneous (Bonilla et al.,
2016; Bogaert et al., 2017a). This article delineates current
knowledge on the molecular genetics of CVID and discusses
strategies for genetic testing in patients diagnosed with CVID.
See also: Immunodeficiency; Immunodeficiency, Primary:
Affecting the Adaptive Immune System; Immunodeficiency
Disorders Due to Antibody Deficiency (B-Lymphocyte
Disorders); B Lymphocytes; Antibodies
Genetic Origin of CVID: ‘Out
of One, Many’
The genetic aetiology of CVID has just started to be unrav-
elled during the last 15 years and is still only partially under-
stood. The majority of CVID cases occur sporadically. About
5–25% of patients have a positive family history, most of which
demonstrate an autosomal dominant (AD) inheritance (Bonilla
et al., 2016). A monogenic cause has, thus far, been identi-
fied in 2–10% of reported patients (Figure 1) (Bogaert et al.,
2016). Each of these genetic subtypes is very rare (Figure 1).
The first CVID-associated disease genes were discovered using
a candidate gene approach based on their central role in B-cell
biology evidenced by single-gene knockout mice. This approach
2 eLS © 2017, John Wiley & Sons, Ltd. www.els.net
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Monogenic cause
(estimated 2–10%)
Unknown genetic cause  
modifier genes (prevalence unknown):
TNFRSF13B (TACI), TNFRSF13C (BAFF-R), MSH5, MSH2,  
MLH1, RAD50, FCGR2A, HLA-DQ/DR, ORC4L, CLEC16A, etc. 
LRBA,
18.80%
NFKB2, 4.70% 
PRKCD, 1.71% 
PLCG2, 1.71% 
NFKB1, 4.27% 
VAV1, 0.43% 
RAC2, 0.43% 
BLK, 0.43% 
MS4A1 (CD20), 0.43% 
CR2 (CD21), 0.85% 
IL21, 0.43% 
CD81, 0.43% 
TNFSF12 (TWEAK), 0.43% 
IKZF1 (IKAROS), 5.56% 
PIK3CD,
20.94%
PIK3R1,
17.95% IL21R, 2.56% 
CD19, 2.99% 
ICOS, 2.99% 
IRF2BP2, 0.43% 
TNFRSF7 (CD27), 3.85% 
CTLA4,
7.69%
Figure 1 Estimated proportion of each disease gene within the CVID population based on published cases. Reproduced with permission from Bogaert
et al. (2016) © BMJ Publishing Group Limited.
mainly uncovered autosomal recessive (AR) genes. In recent
years, next-generation sequencing (NGS) technologies such as
whole exome sequencing (WES) have facilitated the identifica-
tion of both AR and AD disease genes in CVID patients. Parallel
with the gradual elucidation of the genetic basis of CVID, it has
become evident that the clinical diagnosis of CVID is an umbrella
covering a wide range of distinct diseases. Moreover, there is
accumulating data suggesting that the majority of CVID patients
have a complex rather than a Mendelian disorder (Bogaert et al.,
2016). See also:Mendelian Genetic Disorders
Monogenic Causes of CVID
Disease-causing genes (initially)
associated with monogenic forms
of CVID
To date, 22 disease-causing genes have been associated with
monogenic forms of CVID (Table 2, Figure 2) (Bogaert et al.,
2016). Although these genes were initially identified in patients
diagnosed with CVID, they are currently considered to account
for distinct disease entities that have been dissociated from
CVID in the IUIS classification (Table 2). Note that more than
half of these disease entities present T-cell and/or other abnor-
malities besides antibody deficiency and are not categorised as
PADs (Picard et al., 2015). Mutations in most of these genes
are characterised by variable expressivity, that is a variable
phenotype with variable age of onset and severity (Bogaert
et al., 2016). In addition, mutations in some AD genes exhibit
reduced or incomplete penetrance, meaning that not all indi-
viduals with the disease-causing variant(s) will develop disease
(Fliegauf et al., 2015; Kuehn et al., 2014, 2016). For a detailed
description on the genetic, clinical and immunological aspects of
the disease-causing genes associated with monogenic forms of
CVID, readers are referred to our recent review (Bogaert et al.,
2016). A brief overview is provided below and in Table 2. See
also: Genotype-Phenotype Relationships
CD19, CD81 and CD21 (encoded by complement recep-
tor 2, CR2) are B-cell surface molecules that form part of
the B-cell coreceptor complex (Figure 2). CD20 (encoded
by membrane-spanning 4A1, MS4A1) is part of a B-cell sur-
face complex that functions in transmembrane Ca2+ transport
(Figure 2). Biallelic loss-of-function (LOF) mutations in any of
these molecules impair B-cell signal transduction, resulting in a
CVID-like clinical and immunological phenotype (that is a phe-
notype strongly resembling CVID, although not all patients fulfil
the CVID diagnostic criteria) (van Zelm et al., 2006, 2010; Thiel
et al., 2012; Kuijpers et al., 2010). See also: B Lymphocytes:
Receptors
Tumour necrosis factor (TNF)-like weak inducer of apoptosis
(TWEAK) is a cytokine encoded by TNF superfamily member
12 (TNFSF12). Its precise function remains to be uncovered, but
it is believed to mainly exert effects on endothelial and innate
immune cells during inflammatory responses. In one family, an
AD TNFSF12 mutation was shown to interfere with B-cell acti-
vating factor belonging to the TNF family (BAFF)-mediated
signalling in B cells, thereby causing a CVID-like antibody defi-
ciency (Figure 2) (Wang et al., 2013).
Inducible T-cell costimulator (ICOS), interleukin-21 (IL-21),
IL-21 receptor (IL-21R) and CD27 (encoded by TNF recep-
tor superfamily (TNFRSF) member 7, TNFRSF7) are involved
in costimulatory T-cell-B-cell interactions (Figure 2). Biallelic
LOF mutations in these molecules, therefore, affect both T cells
and B cells, causing combined immunodeficiencies (CIDs) with
eLS © 2017, John Wiley & Sons, Ltd. www.els.net 3
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increased susceptibility to opportunistic infections (Grimbacher
et al., 2003; Salzer et al., 2014; Kotlarz et al., 2013; van Mont-
frans et al., 2012). See also:Mixed T- and B-Lymphocyte Defi-
ciency Disorders; Follicular Helper T Cells
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is
an inhibitory T-cell receptor that prevents excessive T-cell
activation and helps regulate immune responses (Figure 2).
CTLA-4 is constitutively expressed by regulatory T cells.
Lipopolysaccharide-responsive beige-like anchor protein
(LRBA) is an intracellular protein located in the vesicular
system of almost all cell types and functions in polarised vesicle
trafficking. LRBA has been recently shown to facilitate traffick-
ing of endosomal CTLA-4 back to the T-cell surface (Figure
2). CTLA-4 and LRBA deficiencies, caused by monoallelic
and biallelic LOF mutations, respectively, are associated with
a similar phenotype of immunodeficiency and severe immune
dysregulation (Kuehn et al., 2014; Schubert et al., 2014; Alan-
gari et al., 2012; Burns et al., 2012; Lopez-Herrera et al., 2012).
CTLA4 mutations are characterised by incomplete penetrance
(Kuehn et al., 2014; Schubert et al., 2014). Curiously, CTLA-4
and LRBA deficiencies have been categorised differently by the
IUIS (Table 2). The IUIS expert committee, however, recognises
that some diseases could fit multiple categories (Picard et al.,
2015). See also: Regulatory T Cells
The nuclear factor of kappa light-chain enhancer of activated
B cells (NF-κB) family of transcription factors is important
for diverse immunological functions. The noncanonical NF-κB2
pathway is activated by a more limited set of receptors compared
with the canonical NF-κB1 pathway (Figure 2). Heterozygous
LOF mutations in NFKB1 and NFKB2 cause antibody deficiency
and autoimmune features, mainly involving skin, hair and nails
(Fliegauf et al., 2015; Chen et al., 2013). NFKB1mutations were
also identified in asymptomatic family members of patients, sug-
gesting incomplete penetrance (Fliegauf et al., 2015).
The phosphatidyl-inositol-3-kinase (PI3K) signalling
molecules play important roles in both B-cell and T-cell function
(Figure 2). Heterozygous gain-of-function (GOF) mutations in
the PI3K catalytic subunit p110δ (encoded by PIK3CD) cause
overactivation of the PI3K pathway, leading to various degrees of
antibody deficiency and increased risk of B-cell lymphoma. This
disease is named activated PI3Kδ syndrome (APDS) (Angulo
et al., 2013). Heterozygous LOF mutations in the PI3K regula-
tory subunit p85α (encoded by PIK3R1) that specifically disrupts
the domain responsible for p110δ inhibition have been shown to
cause an APDS-like phenotype (Deau et al., 2014; Lucas et al.,
2014).
Protein kinase C delta (PKCδ, encoded by PRKCD), phospho-
lipase C gamma 2 (PLC𝛾2, encoded by PLCG2), B lymphoid
tyrosine kinase (BLK), Vav1 guanine nucleotide exchange factor
(VAV1) and Ras-related C3 botulinum toxin substrate 2 (RAC2)
are intracellular molecules involved in signalling processes
downstream of the B-cell receptor (Figure 2). PKCδ deficiency
causes an immune dysregulation disorder with autoimmunity
and lymphoproliferation (Salzer et al., 2013). Heterozygous
GOF mutations in PLCG2 cause an autoinflammatory disease
termed PLC𝛾2-associated antibody deficiency and immune
dysregulation (PLAID) (Ombrello et al., 2012). BLK, VAV1
and RAC2 deficiencies have each been reported in one family
with a CVID-like phenotype (Capitani et al., 2012; Alkhairy
et al., 2015; Compeer et al., 2015). See also: B Lymphocytes:
Receptors
IKAROS, encoded by IKAROS family zinc finger pro-
tein 1 (IKZF1), is a transcription factor essential in human
haematopoiesis and B-cell development (Figure 2). Heterozy-
gous LOF mutations have been associated with CVID and other
forms of antibody deficiency and are characterised by incomplete
penetrance (Kuehn et al., 2016; Hoshino et al., 2016).
Finally, heterozygous GOF mutations in interferon regulatory
factor 2 binding protein 2 (IRF2BP2) were identified in one
CVID-affected family. Although its exact function is unclear,
IRF2BP2 is thought to function as a negative regulator of the
transcription factor nuclear factor of activated T cells (Figure 2)
(Keller et al., 2016).
Disease-causing genes associated
with other monogenic PIDs
CVID is a diagnosis of exclusion and should only be given
after other causes of antibody deficiency have been ruled out.
CVID-reminiscent antibody deficiency is, however, seen in a con-
siderable number of PIDs and can sometimes be the most promi-
nent manifestation in the initial stages of the disease, whereas
disease-specific features are not yet present or may be less appar-
ent. Therefore, patients with other well-defined monogenic PIDs
may initially (appear to) fulfil the diagnostic criteria of CVID
(Bogaert et al., 2016; Bonilla et al., 2016). Here, we highlight
examples from recent literature reports including patients diag-
nosed with CVIDwhowere later found to havemutations in other
PID genes.
GATA2 deficiency, caused by heterozygous LOF mutations in
GATA-binding protein 2 (GATA2), is a PID disease characterised
by monocytopenia, B and NK lymphopenia, reduced dendritic
cells, myelodysplasia and lymphedema. Cellular deficiencies can
evolve over time as was recently described in a boy in whom a
CVID phenotype in early childhood developed into a complete
GATA2-deficient phenotype in adolescence (Chou et al., 2014).
See also: Immunodeficiency
Heterozygous GOF mutations in signal transducer and activa-
tor of transcription 1 (STAT1) typically underlie chronic muco-
cutaneous candidiasis, bacterial infections of the respiratory tract
and skin, and autoimmunemanifestations. A 10-year-old boy was
diagnosedwith CVID because of low serum Igs, impaired vaccine
responses, low B cells, recurrent airway infections and recurrent
episodes of mucocutaneous candidiasis. WES was required to
reach a conclusive diagnosis of a STAT1 GOF disorder (Kobbe
et al., 2016). See also: Immunodeficiency
Monoallelic LOF mutations in phosphatase and tensin
homolog (PTEN) cause a rare familial cancer syndrome known
as PTEN hamartoma tumour syndrome or Cowden syndrome.
In addition to multiple hamartomas and an increased risk of
developing certain types of cancer, some patients demonstrate
defects in the adaptive immune system. Recently, there have
been several case series on patients with PTEN deficiency,
presenting varying degrees of antibody deficiency, autoimmunity
and lymphoproliferative disease. Given the phenotypic overlap,
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some of these patients had received a prior diagnosis of CVID or
APDS (Driessen et al., 2016; Tsujita et al., 2016).
Syndromic PIDs can sometimes mimic CVID in infants and
toddlers when syndromic features have not yet been diagnosed.
This was recently demonstrated in familial cases of lysine methyl-
transferase 2A (KMT2A)-associated Wiedemann-Steiner syn-
drome and RNA U4atac small nuclear (U12-dependent splic-
ing) (RNU4ATAC)-associated Roifman syndrome (Bogaert et al.,
2017b).
Hypomorphic mutations in genes historically associated with
severe combined immunodeficiency (SCID) can result in a milder
phenotype resembling CVID. This was recently described for
the genes recombination activating gene 1 (RAG1), interleukin
2 receptor gamma chain (IL2RG), janus kinase 3 (JAK3) and
DNA cross-link repair 1C (DCLRE1C; encoding ARTEMIS)
(Buchbinder et al., 2015; Abolhassani et al., 2014, 2015; Volk
et al., 2015; Chandra et al., 2016). See also: Immunodeficiency:
Severe Combined Immunodeficiency Disease; Mixed T- and
B-Lymphocyte Deficiency Disorders
Complex or Multifactorial
Aetiology of CVID
There is increasing evidence that besides rare monogenic sub-
types, CVID is a complex trait in which multiple genetic,
epigenetic and/or environmental factors are involved in both
primary antibody deficiency and disease-related complica-
tions. Elements that strengthen the hypothesis of CVID having
a multifactorial aetiology are late onset of disease, sporadic
occurrence in the majority of cases, variable expressivity and/or
incomplete penetrance of monogenic defects and the finding of
monogenic variants in the general population (Bogaert et al.,
2016). Currently available data implicating a complex molecular
basis in the majority of CVID patients is laid out below. See
also: Molecular Basis of Complex Traits; Complex Genetic
Systems and Diseases
Modiﬁer genes associated with CVID
Variants in particular genes seem to be present at a higher fre-
quency in CVID patients compared with the general population.
These variants by themselves are not sufficient to establish a
CVID phenotype but could increase the risk of disease develop-
ment and/or influence the phenotypic manifestations in a patient.
The genes in which such variants occur are called modifier genes
(Figure 1) (Bogaert et al., 2016).
Transmembrane activator and calcium modulator and
cyclophilin ligand interactor (TACI, encoded by TNFRSF13B)
and BAFF receptor (BAFF-R, encoded by TNFRSF13C)
are related B-cell surface receptors important in peripheral
B-cell homoeostasis (Figure 2). TACI mediates T-independent
class-switch recombination and terminal differentiation into
plasma cells and also exhibits immunoregulatory functions.
Mono- and biallelic variants in the gene encoding TACI were ini-
tially reported to be fully penetrant (Castigli et al., 2005; Salzer
et al., 2005). Although biallelic TNFRSF13B variants are usually
associated with some degree of antibody deficiency, monoallelic
variants are also observed in 1–2% of the general population.
Still, monoallelic TNFRSF13B variants can increase the risk
of developing CVID and autoimmune phenomena by compro-
mising TACI function. Noteworthy, monoallelic p.C104R and
p.A181E account for 80% of all TNFRSF13B variants identified
in CVID patients (Pan-Hammarstrom et al., 2007; Salzer et al.,
2009). BAFF-R, on the other hand, mainly facilitates peripheral
B-cell survival. Mono- and biallelic TNFRSF13C variants seem
to occur more frequently in the CVID population. More than 90%
of all reported cases were heterozygous or homozygous for the
p.P21R variant, which reduces binding of BAFF-R to its ligand
(Pieper et al., 2014). Complete BAFF-R deficiency, caused by a
homozygous intragenic deletion in TNFRSF13C, has only been
reported in one kindred with late-onset CVID (Warnatz et al.,
2009). Because both mono- and biallelic TNFRSF13C variants
are also commonly detected in healthy individuals, they are not
believed to be disease-causing but rather predispose to disease
development and/or influence the final phenotype (Pieper et al.,
2014). For a more in-depth discussion on the role of TNFRSF13B
and TNFRSF13C variants in CVID, we refer to our recent review
(Bogaert et al., 2016).
Furthermore, variants in DNA (deoxyribonucleic acid) repair
genes such as MutS homolog 5 (MSH5), MSH2, MutL homolog
1 (MLH1), RAD50 double-strand break repair protein (RAD50)
and MRE11 homolog double-strand break repair nuclease
(MRE11) as well as inFc fragment of IgG receptor IIa (FCGR2A)
were found to be significantly associated with CVID. The relative
contribution of these genetic variations in the development of
CVID awaits further study (Offer et al., 2010; Flinsenberg et al.,
2014).
Finally, variants in particular genes do not increase suscepti-
bility to CVID per se but may increase the risk of developing
disease-related complications. For example, a nucleotide-binding
oligomerisation domain-containing protein 2 (NOD2) variant
was associated with the development of chronic enteropathy, an
autoimmune regulator (AIRE) variant with various autoimmune
manifestations and an NLR family pyrin domain containing 12
(NLRP12) variant with juvenile idiopathic arthritis and gastroin-
testinal amyloidosis in patients who fulfilled the CVID diagnostic
laboratory criteria (Packwood et al., 2010; Bellacchio et al., 2014;
Borte et al., 2014).
Polygenic basis of CVID
Since certain monogenic variants are thought to contribute to
the development of CVID but do not suffice to establish dis-
ease, variants in multiple genes must be involved. In a recent
study, sporadic CVID patients demonstrated a mutational bur-
den in shared genes and pathways implicated in B-cell biology
(van Schouwenburg et al., 2015). The authors reported that each
patient had an average of 9.4 variants possibly contributing to
the disease phenotype. Future pathway and network analyses in
larger CVID cohorts could help determine the collective con-
tribution of genetic variants that individually do not suffice to
establish disease. Furthermore, the combination of whole genome
sequencing (WGS) and RNA (ribonucleic acid) sequencing in
three sporadic CVID cases suggested that noncoding variation
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and differential gene expression could play a role in the patho-
genesis of CVID (van Schouwenburg et al., 2015).
Risk loci associated with CVID
So far, two genome-wide association studies (GWAS) have been
performed in CVID cohorts. The first GWAS identified a signif-
icant association with the human leucocyte antigen (HLA) locus
consistent with findings from previous genetic linkage studies
(Orange et al., 2011). CVID patients were also found to have a
significantly higher burden of copy number variations (CNVs)
compared with controls, with intraexonic duplications in origin
recognition complex subunit 4 (ORC4L) being most highly asso-
ciatedwith disease. CNVs have not yet been systematically exam-
ined in CVID patients. The 2011GWAS data set was used to build
an algorithmic model for predicting the risk of developing CVID.
Although the internal validation test was successful and identified
CVID patients with 98.7% accuracy, the prediction model has,
to our knowledge, not been used in other study cohorts (Orange
et al., 2011). The second GWAS confirmed the association with
the HLA locus and detected additional significant associations
with loci containingCD21, ICOS, TNFRSF13B (encoding TACI),
MSH5 and C-type lectin domain containing 16A (CLEC16A) (Li
et al., 2015). TheCLEC16A locus had previously been reported as
a genetic susceptibility locus for complex autoimmune diseases.
Shared loci such as those containing CLEC16A could provide
clues to further unravel the cooccurrence of B-cell deficiency
and autoimmunity in patients with CVID (Li et al., 2015). See
also: Genome-Wide Association Studies; Human Leukocyte
Antigen (HLA) System and Human Disorders; Genetic Sus-
ceptibility to Autoimmune Disorders
Epigenetic changes in CVID
Epigenetic modifications alter gene expression without chang-
ing the DNA sequence itself. DNA methylation is one of the
mechanisms of epigenetic modification in humans. Monozygotic
twins discordant for CVID have provided evidence that epige-
netic changes could also play a role in the development of CVID
(Rodriguez-Cortez et al., 2015). In particular, the CVID-affected
twin showed impaired DNA demethylation in key genes covering
multiple B-cell functions. Subsequent analyses in a larger cohort
confirmed that B cells of CVID patients had less demethylation of
these key genes during differentiation from naive to memory-type
cells compared with B cells of healthy controls. Epigenetic pro-
cesses are, in turn, influenced by environmental factors such as
smoking, diet and infectious agents. Consequently, the risk of
developing CVID may be determined by a complex interplay
between (multiple) genetic components and environmental influ-
ences. See also: Epigenetic Variation in Humans
Importance of a Genetic Diagnosis
Based on the current literature, it is estimated that 2–10% of
CVID patients have an underlying monogenic cause, whereas the
majority of patients seem to have a complex aetiology (Bogaert
et al., 2016). However, considering current advances in genomic
technologies, we expect that the proportion of CVID patients with
a monogenic cause will increase to some extent. As explained
above, patients in whom a monogenic defect is identified are
no longer regarded as CVID but are removed from under the
umbrella. Nonetheless, identifying amonogenic defect in a CVID
patient enables genetic counselling and reproductive options and
can also entail important implications for patient management.
In particular, when the gene has already been described in other
patients, knowing the genetic defect helps to assess the prog-
nosis of the patient and to guide follow-up with screening for
disease-specific complications (Bogaert et al., 2016). See also:
Genetic Counselling
Ig replacement therapy, the current cornerstone of treatment,
significantly decreases the infection frequency but has little effect
on disease-related complications (Bonilla et al., 2016). There-
fore, other treatment modalities are being explored. In some
monogenic subtypes (e.g. LRBA and PIK3CD), haematopoietic
stem cell transplantation (HSCT) is now considered an accept-
able treatment option (Seidel et al., 2015; Coulter et al., 2017).
In clinical practice, the decision to perform high-risk HSCT in
CVID patients with a severe clinical course often hinges on the
identification of the underlying genetic defect, underlining the
importance of an early genetic diagnosis.Moreover, the discovery
of monogenic defects has improved our understanding on cellular
pathways that are affected, opening the door to targeted drug ther-
apies. Some existing immunomodulatory drugs could be repur-
posed, such as the use of the CTLA-4mimetic abatacept in LRBA
and CTLA-4 deficiencies and mTOR inhibitors in APDS (Vig-
nesh et al., 2017). In addition, novel targeted drugs can be devel-
oped, such as PI3K p110δ-specific inhibitors in patients with
APDS for which two clinical trials have been recently announced
(Lucas et al., 2016).
Strategies for Genetic Testing
in Monogenic Forms of CVID
A monogenic cause of CVID is more probable in case of early
onset of disease, features of immune dysregulation such as
autoimmunity or lymphoproliferation, a positive family history
and/or consanguinity (Bogaert et al., 2016). We here propose
strategies for genetic testing in patients with a CVID(-like) phe-
notype in whom a monogenic cause is suspected.
DNA sequencing
Molecular genetic testing mainly involves screening for DNA
sequence alterations. Since the 1980s, Sanger sequencing has
been the gold standard for DNA-based screening of disease genes.
In the past decade, massively parallel sequencing or NGS tech-
nologies evolved, enabling the simultaneous analysis of millions
of DNA sequences (Goodwin et al., 2016). Targeted sequencing
of a small number of genes can be performed if the patient’s
phenotype is suggestive of specific genotype-phenotype cor-
relations. Such phenotype-genotype correlations are, however,
rarely observed in CVID patients. As elaborated above, CVID
is a genetically heterogeneous disorder and shows considerable
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phenotypic overlap with other well-defined PID disorders. The
situation is further complicated by non-Mendelian phenomena
such as variable expressivity and incomplete penetrance (Bogaert
et al., 2016). NGS-based targeted resequencing of gene panels
enables screening of all PID-associated genes at the same time,
but these are very hard to keep up to date because of the high pace
at which new PID genes are currently discovered. Furthermore,
such gene panels limit the discovery of new disease-causing
genes making them less attractive for research purposes (Nijman
et al., 2014). Therefore, WES is currently the most cost-effective
approach both from a clinical and from a research point of view.
WES aims to sequence all coding exons (collectively called the
exome) in a single person and offers the flexibility that is needed
in the rapidly evolving field of PID. WES data can first be
analysed for known (that is published) and/or candidate disease
genes by filtering against a list of genes. Such lists can be easily
expanded without having to change the sequencing procedure. If
no pathogenic variants are identified, an exploratory analysis of
the completeWES data can be performed afterwards (Conley and
Casanova, 2014; Fang et al., 2016). The number of WES variants
can be reduced by filtering the patient’s WES data against those
from affected and/or nonaffected family members. Caution is
warranted, however, taking into account variable expressivity and
incomplete penetrance. The main limitation of WES is that not
all coding regions are sufficiently covered by the capture-based
enrichment method. WGS has several technical advantages over
WES and also allows the identification of structural variants
and variants in noncoding regions. Since the costs for WGS are
steadily going down, this technique will most likely replaceWES
in the near future in genetic laboratories worldwide (Conley and
Casanova, 2014; Goodwin et al., 2016). See also: Application
of Exome Sequencing to Mendelian Disorders and the Emer-
gence of Personalised Medicine; Next-generation Sequencing
in Clinical Molecular Diagnostics; Bioethics of Genetic and
Genomic Testing
CNV analysis
CNVs are an important source of structural variation. Moreover,
a recent report on 278 PID index patients has detected several
PID-causing CNVs of which somewere intragenic CNVs smaller
than 30 kb (Stray-Pedersen et al., 2017). CNVs should thus be
actively investigated in all patients diagnosed with CVID. A com-
monly used technique to screen for CNVs is array comparative
genomic hybridisation (aCGH). A disadvantage of aCGH is that it
usually detects large CNVs (larger than 1 kb). NGS data can also
be used to detect CNVs using specific algorithms (Zhao et al.,
2013). See also: Comparative Genomic Hybridization in the
Study of Human Disease
Homozygosity mapping in case
of consanguinity
Homozygosity mapping, also called autozygosity mapping or
identity-by-descent (IBD) mapping, is used to identify large
homozygous genomic regions in patients with a consanguineous
background, based on the assumption that the causal mutation
is homozygous and located in a run of homozygosity identical
by descent. Runs of homozygosity or IBD regions can be deter-
mined by means of genome-wide single nucleotide polymor-
phism (SNP) chip arrays or can be derived from NGS data using
particular algorithms (Alkuraya, 2010; Szpiech et al., 2013).
Mutation analysis can be performed for all genes located in the
IBD regions that could be associatedwith the patient’s phenotype.
Alternatively, the IBD regions can be used to guide WES/WGS
data analysis in which case only candidate variants located in
the IBD regions are retained (Alkuraya, 2013). Giving the poor
phenotype-genotype correlations in CVID patients, the combina-
tion of IBD mapping with WES/WGS is preferred. To narrow
down the number and length of the IBD regions from a patient,
IBD mapping can also be performed in affected and/or nonaf-
fected siblings.
Interpretation of sequence variants
and CNVs
The American College of Medical Genetics and Genomics
(ACMG) has published guidelines and recommendations for the
interpretation of sequence variants and CNVs (Kearney et al.,
2011; Richards et al., 2015). Evidence can be retrieved from
various sources including medical literature, inheritance (e.g.
segregation in the family), population databases, disease-specific
databases, locus (gene)-specific databases and computational
prediction programs. Databases contain useful information but
need to be handled with care. Population databases are known to
include both benign and pathogenic variants and do not provide
detailed information on associated phenotypes or functional
effects. Variants reported in disease- and locus-specific databases
can be classified incorrectly because the entered data is usually
not reviewed. Furthermore, the performance and accuracy of
computational prediction programs varies greatly. The combi-
nation of multiple in silico predictive algorithms is, therefore,
considered as a single and supportive piece of evidence by
the ACMG. For a more detailed description on the available
databases and in silico prediction tools, we refer the reader to
the ACMG publications (Kearney et al., 2011; Richards et al.,
2015). A list of locus-specific databases that can be used to
look up specific CVID genes is accessible on https://grenada.
lumc.nl/LSDB_list/lsdbs. Given the complexity of the interpre-
tation of genetic variation, close collaboration between referring
health care providers and trained geneticists is indispensable.
Conclusion
The molecular basis of CVID is only beginning to be unravelled.
Studies, so far, have focused on identifying monogenic defects in
CVID patients. In addition, a few genome-wide and epigenetic
studies have addressed the hypothesis of a complex aetiology
of CVID. Considering the substantial phenotypic overlap with
other PIDs, health care providers and scientists should be aware
that a clinical diagnosis of CVID is not the end point of the
diagnostic process and that continuous clinical reevaluation and
genetic testing should be pursued. A genetic diagnosis often
holds important opportunities for guiding follow up, treatment
decisions and genetic counselling.
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Glossary
Allele An alternative form of a gene; monoallelic involves a
single allele and biallelic involves both alleles.
Epigenetic Changes in gene expression that do not entail
changes in DNA sequence, can be mitotically and/or
meiotically inherited.
Genotype The genetic makeup of a cell or organism.
Hypomorphic mutation A type of mutation that reduces but
does not completely abolish the activity of the gene product.
Immune dysregulation Disturbed immune homeostasis,
dysfunction of the immune system.
Incomplete (or reduced) penetrance Not all individuals with a
mutant genotype develop a disease phenotype.
Locus A unique location on a chromosome.
Modifier gene A gene that alters the phenotypic expression of
another gene.
Phenotype The observable characteristics of an organism.
Variable expressivity The same primary genotype is associated
with a variable phenotypic expression.
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